Novo Nordisk (NVO) remains a strong buy in the weight loss/diabetes market despite challenges. Read here for an investment ...

Novo Nordisk NVO announced that it has submitted a regulatory filing seeking label expansion for a higher dose of its ...

Through the FDA’s priority voucher program, Novo Nordisk said Nov. 26 it has filed an application seeking approval of its Wegovy 7.2 milligram injection.  Wegovy (semaglutide) is currently approved in ...

Novo Nordisk files for FDA review of its higher-dose Wegovy after 72-week data show stronger weight loss than the current 2.4 ...

In a rapidly heating market, Otsuka is the first to secure FDA clearance for an "anti-APRIL" therapy targeting IgA ...

Novo Nordisk is using its ticket for an extra-speedy regulatory review granted through the FDA’s Commissioner’s National ...

Novo Nordisk is also currently awaiting a decision from the FDA, having previously applied for approval of its Wegovy weight-loss pill. As part of the U.S. pricing deal with the administration earlier ...

The Food and Drug Administration is set to treat the application under its priority program to accelerate the review of ...

Novo has experienced a prolonged sell.off over the last months, declining more than 65% from all-time highs. Why some kind of ...

The executive who brought Novo Nordisk A/S’s first weight-loss shot to market is coming back as chairman of the Danish drugmaker, and not all shareholders are happy about it. Investors are meeting on ...

Eli Lilly and Novo Nordisk’s competition in weight-loss drugs has affected thousands of jobs between Charlotte and Raleigh.